Back to Search
Start Over
Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
- Source :
-
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2016 Jul; Vol. 75 (1), pp. 99-105. Date of Electronic Publication: 2016 Mar 24. - Publication Year :
- 2016
-
Abstract
- Background: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life.<br />Objective: We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis.<br />Methods: A post hoc analysis of data pooled from phase IIb (PSOR-005) and phase III (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1 and 2) clinical studies was conducted to determine the effect of apremilast 30 mg twice daily versus placebo at week 16 in a subset of patients with moderate to severe plaque psoriasis with active palmoplantar psoriasis (baseline Palmoplantar Psoriasis Physician Global Assessment [PPPGA] score ≥1).<br />Results: Significantly more patients taking apremilast with moderate to severe palmoplantar psoriasis (baseline PPPGA score ≥3) achieved PPPGA score 0 (clear) or 1 (almost clear) compared with placebo at week 16 (48% vs 27%; P = .021). At week 16, 46% of the apremilast group with baseline PPPGA score 1 or higher achieved a PPPGA score of 0 versus 25% of the placebo group (P < .001); 59% of the apremilast group had a PPPGA score of 0 or 1 with 1-point or more improvement versus 39% receiving placebo (P < .001).<br />Limitations: This post hoc analysis was limited to 16 weeks and did not assess palmoplantar pustules, lesion localization, or surface area involvement.<br />Conclusion: Apremilast may be a useful oral treatment option for patients with moderate to severe palmoplantar plaque psoriasis.<br /> (Copyright © 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Administration, Oral
Adult
Double-Blind Method
Female
Foot Dermatoses pathology
Hand Dermatoses pathology
Humans
Male
Middle Aged
Phosphodiesterase 4 Inhibitors administration & dosage
Phosphodiesterase 4 Inhibitors adverse effects
Psoriasis pathology
Severity of Illness Index
Thalidomide administration & dosage
Thalidomide adverse effects
Thalidomide therapeutic use
Foot Dermatoses drug therapy
Hand Dermatoses drug therapy
Phosphodiesterase 4 Inhibitors therapeutic use
Psoriasis drug therapy
Thalidomide analogs & derivatives
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6787
- Volume :
- 75
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Academic Journal
- Accession number :
- 27021239
- Full Text :
- https://doi.org/10.1016/j.jaad.2016.02.1164